Public Assessment Report. Scientific discussion. Ramipril Teva 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets Ramipril DK/H/2130/ /DC.

Size: px
Start display at page:

Download "Public Assessment Report. Scientific discussion. Ramipril Teva 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets Ramipril DK/H/2130/001-004/DC."

Transcription

1 Public Assessment Report Scientific discussion Ramipril Teva 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets Ramipril DK/H/2130/ /DC 3 April 2014 Tis module reflects te scientific discussion for te approval of Ramipril Teva. Te procedure was finalised on 13 Marc For information on canges after tis date please refer to te module Update.

2 I. INTRODUCTION Based on te review of te quality, safety and efficacy data, te Member States ave granted a marketing autorisation for Ramipril Teva 1.25 mg, 2.50 mg, 5 mg and 10 mg tablets, from Teva Denmark A/S. Te product is indicated for treatment of ypertension, renal desease and symptomatic eart failure, cardiovascular prevention and secondary prevention after acute myocardial infarction. A compreensive description of te indications and posology is given in te SmPC. Ramipril is an angiotensin-converting enzyme (ACE) inibitor tat requires cleavage of an ester group to form te active metabolite ramiprilat wic inibits te conversion of angiotensin I to te more active angiotensin II. Tis decentralised procedure concerns a generic application claiming essential similarity wit te reference product Triatec 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets, wic as been registered in Denmark by Sanofi-aventis Denmark A/S since January Triatec 10 mg tablets are no longer registered in Denmark. Triatec 10 mg is autorised in te form of ard capsules by sanofi-aventis Denmark A/S since November Te reference products used for te bioequivalence studies are Delix 2.5 mg tablets, Hoecst AG and Delix protect 10 mg tablets, Aventis Parma Deutscland GmbH, bot from te German market. Te marketing autorisation as been granted pursuant to Article 10(1) of Directive 2001/83/EC. II. QUALITY ASPECTS II.1 Introduction Eac tablet contains ramipril 1.25 mg, 2.5 mg, 5 mg or 10 mg. Te 1.25 mg tablets are yellow, oblong, biplane tablets, 8.0 mm x 4.0 mm. Te 2.5 mg tablets are yellow, capsule-saped, un-coated, flat tablets, 10.0 x 5.0 mm, scored on one side and side walls, marked R2. Te 5 mg tablets are pink, capsule-saped, un-coated, flat tablets, 8.8 x 4.4 mm, scored on one side and side walls, marked R3. Te 10 mg tablets are wite to off-wite, capsule-saped, un-coated, flat tablets, 11.0 x 5.5 mm, scored on one side and side walls, marked R4. Te 2.5 mg, 5 mg and 10 mg tablets can be divided into equal alves. Te tablets are packed in blister packs of OPA/Al/PVC-Al in pack sizes of 7, 20, 21, 28, 30, 50, 56, 60, 90, 98, 100 and 50x1 tablets. However, not all pack sizes may be marketed. Te excipients in te tablets are: sodium ydrogen carbonate; lactose monoydrate; croscarmellose sodium; starc, pregelatinised (from maize starc); sodium stearyl fumarate; iron oxide yellow (E172) (1.25 mg, 2.5 mg and 5 mg tablets only) and iron oxide red (E172) (5 mg tablets only). Te RMS as been assured tat acceptable standards of GMP (see Directive 2003/94/EC) are in place for tis product type at all sites responsible for te manufacturing of te active substance as well as for te manufacturing and assembly of tis product prior to granting its national autorisation. 2/7

3 II.2 Drug Substance Te active substance ramipril is manufactured by two different external suppliers eac olding a CEP. Te active substance is controlled according to te requirements of te P. Eur. monograp and te CEPs. Stability data are provided by bot ASMs wit proposed storage conditions and re-test periods. Based on stability data provided, te proposed re-test periods and storage conditions ave been justified and accepted. II.3 Medicinal Product Te overall parmaceutical development of te drug product is based on te minimal approac to parmaceutical development cf. ICH Q8 guidance. Te development of te product is described in brief, te coice of excipients is justified and teir functions explained. Te preference of wet granulation for te manufacture of te drug product as been indicated. Validation protocols are presented. Validation data for te tablet strengts ave been presented to support te proposed batc sizes. Te drug product specifications cover appropriate parameters for tis dosage form. Te control tests and specifications for te drug product are adequately drawn up. Validations of te analytical metods are presented. Te batc analysis results demonstrate tat te drug product meets te proposed specifications and confirm consistency of te drug product. Dissolution data of te drug product ave been provided demonstrating similarity of dissolution in te entire ph range. Te conditions used in te stability studies are according to te ICH stability guideline. A justification for not providing potostability studies in accordance wit ICH as been provided. Te following self-lives/storage conditions ave been approved: 1.25 mg tablets: 18 monts/do not store above 25 C. Store in te original package in order to protect from moisture and ligt. 2.5 mg, 5 mg and 10 mg tablets: 2 years/do not store above 25 C. Store in te original package in order to protect from moisture and ligt. III. NON-CLINICAL ASPECTS III.1 Introduction Parmacodynamic, parmacokinetic and toxicological properties of ramipril are well known. As ramipril is a widely used, well-known active substance, te applicant as not provided additional studies and furter studies are not required. Overview based on literature review is, tus, appropriate. Te non-clinical overview report refers 37 publications up to year Te non-clinical overview on te pre-clinical parmacology, parmacokinetics and toxicology is adequate. III.2 Ecotoxicity/environmental risk assessment (ERA) Since Ramipril Teva is intended for generic substitution, tis will not lead to an increased exposure to te environment. An environmental risk assessment is terefore not deemed necessary. 3/7

4 IV. CLINICAL ASPECTS IV.1 Introduction Ramipril is a well-known active substance wit establised efficacy and tolerability. As ramipril is a widely used, well-known active substance, te applicant as not provided additional studies (apart from supportive bioequivalence studies referenced below) and furter studies are not required. Overview based on literature review is, tus, appropriate. Te clinical overview report refers 97 publications up to year Te clinical overview on te clinical parmacology, efficacy and safety is adequate. IV.2 Parmacokinetics To support te application, te applicant as submitted 2 bioequivalence studies. Te following study as been submitted in support of te 2.5 mg tablet strengt: Fasting study: Single-dose of 5 mg (2x2.5 mg), Delix 2.5 mg tablets, Hoecst AG, from te German market, compared to 2x2.5 mg of Ramipril Teva tablets. Te following study as been submitted in support of te 10 mg tablet strengt: Fasting study: Single-dose, Delix PROTECT 10 mg tablets, Aventis Parma Deutscland GmbH, from te German market, compared to 10 mg of Ramipril Teva tablets. Biowaiver Tablet strengt 2.5 mg is dose proportional to tablet strengt 1.25 mg wile tablet strengt 10 mg is dose proportional to tablet strengt 5 mg. Te applicant concludes bioequivalence of te oter tablet strengts 1.25 mg and 5 mg mg based on te submitted bioequivalence studies for tablet strengts 2.5 mg and 10 mg, respectively. Reference is made to Guideline on Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1). Bioequivalence studies Single-dose study of 5 mg (2x2.5 mg) Te study was an open-label, randomized, two-treatment, two-sequence, two-period, two-way crossover, single-dose bioavailability study conducted under fasting conditions wit a was out period of 28 days between te two periods. 2x2.5 mg was administered in eac period. Blood samples were collected pre-dosing and at various time-points up to 120 ours post administration of a single-dose 2x2.5 mg tablets wit 240 ml of water for te analyses of active metabolite ramiprilat. Samples up to 16 ours post administration were analysed for parent compound ramipril. 38 ealty adults (18 males/20 females), 37 Caucasians and 1 black, aged between 23 and 55 participated in te study. 38 subjects completed te study. Analytical results of 35 subjects were available for statistical and parmacokinetic analysis. Te parmacokinetic parameters calculated for ramipril and ramiprilat were:,, AUC 0- t,/,,, K el, t 1/2. Bioequivalence was based on evaluation of te 90% geometric CI T/R for -transformed, and for ramiprilat. Acceptance criteria: 80.00% to %. 4/7

5 Results Table 1. Summary statistics of parmacokinetic parameters N=35 Treatment Ramipril ng*/ml ng*/ml ng/ml ng*/ml ng*/ml Test [43.7] [45.5] [47.9] [30.8] [19.0] [27.0] Reference [45.7] [44.7] [50.5] [23.9] [20.2] [24.9] T/R Ratio 99.2% 102.4% 90.8% % 101.3% (90% CI) (94.3- (96.6- (81.3- (97.3- ( %) 108.4%) 101.5%) 102.8%) 105.8%) Area under te plasma concentration curve from administration to last observed concentration at time t. Area under te plasma concentration curve extrapolated to infinite time. does not need to be reported wen AUC 0-72 is reported instead of Maximum plasma concentration Time until is reaced Ramiprilat ng/ml [45.5] [51.0] 102.3% ( %) [34.4] [42.0] - Single-dose study of 10 mg Te study was an open-label, randomized, two-treatment, two-sequence, two-period, two-way crossover, single-dose bioavailability study conducted under fasting conditions wit a was out period of 28 days between te two periods. 1x10 mg was administered in eac period. Blood samples were collected pre-dosing and at various time-points up to 120 ours post administration of a single-dose (1x10 mg tablet) wit 240 ml of water for te analyses of active metabolite ramiprilat. Samples up to 16 ours post administration were analysed for parent compound ramipril. 38 ealty adults (32 males/6 females), 37 Caucasians and 1 black, aged between 19 and 55 were enrolled in te study. 36 subjects completed te study. Analytical results of 36 subjects were available for statistical and parmacokinetic analysis. Te parmacokinetic parameters calculated for ramipril and ramiprilat were:,, AUC 0- t,/,,, K el, t 1/2. Bioequivalence was based on evaluation of te 90% geometric CI T/R for -transformed, and for ramiprilat. Acceptance criteria: 80.00% to %. Results Table 1. Summary statistics of parmacokinetic parameters N=36 Treatment ng*/ml Test [44.2] Reference [45.4] T/R Ratio 106.0% (90% CI) ( %) ng*/ml [43.3] [44.0] 106.1% ( %) Ramipril ng/ml [60.6] [59.4] 106.0% ( %) ng*/ml [40.2] [29.4] [38.5] [26.8] % ( %) ng*/ml [29.1] [28.8] 105.2% ( %) Ramiprilat ng/ml [67.4] [60.2] 106.0% ( %) [34.8] [43.1] - 5/7

6 Area under te plasma concentration curve from administration to last observed concentration at time t. Area under te plasma concentration curve extrapolated to infinite time. does not need to be reported wen AUC 0-72 is reported instead of Maximum plasma concentration Time until is reaced Conclusion on bioequivalence studies Based on te submitted bioequivalence studies Ramipril Teva 2.5 mg and 10 mg tablets are considered bioequivalent wit Delix 2.5 mg and 10 mg tablets. Biowaivers for te additional tablet strengts ave been justified. Te RMS as been assured tat te bioequivalence study as been conducted in accordance wit acceptable standards of Good Clinical Practice (GCP, see Directive 2005/28/EC) and Good Laboratory Practice (GLP, see Directives 2004/9/EC and 2004/10/EC). IV.3 Risk management plan & Parmacovigilance system Ramipril was first approved in 1989, and tere is now more tan 10 years postautorisation experience wit te active substance. Te safety profile of ramipril can be considered to be well establised and no product specific parmacovigilance issues were identified pre- or postautorisation wic are not adequately covered by te current SPC. Additional risk minimisation activities ave not been identified for te reference medicinal product. Te MAH as a parmacovigilance system at teir disposal, wic is based on te current European legislation. Te Parmacovigilance system described fulfils te requirements and provides adequate evidence tat te applicant as te services of a qualified person responsible for parmacovigilance and as te necessary means for te identification and notification of any a potential risks occurring eiter in te Community or in a tird country. V. USER CONSULTATION A user consultation wit target patient groups on te package information leaflet (PIL) as been performed on te basis of a bridging report making reference to Ramipril ratioparm, DK/H/0543/ /MR. Te bridging report submitted by te applicant as been found acceptable. VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION Ramipril Teva 1.25 mg, 2.50 mg, 5 mg and 10 mg tablets as a proven cemical-parmaceutical quality and is a generic form of Triatec. Triatec is a well-known medicinal product wit an establised favourable efficacy and safety profile. Bioequivalence as been sown to be in compliance wit te requirements of European guidance documents. Te MAH as provided written confirmation tat systems and services are in place to ensure compliance wit teir parmacovigilance obligations. Agreement between Member States was reaced during a written procedure. Tere was no discussion in te CMD(). Te Concerned Member States, on te basis of te data submitted, considered tat essential similarity as been demonstrated for Ramipril Teva wit te reference product, and ave 6/7

7 terefore granted a marketing autorisation. Te decentralised procedure was finalised on 13 Marc Ramipril Teva was autorised in Denmark on 22 April According to te List of Union reference dates and frequency of submission of periodic safety update reports (PSURs), no PSURs are required for tis product. Te date for te first renewal will be: 13 Marc Tere were no post-approval commitments made during te procedure. 7/7

Public Assessment Report. Scientific discussion. Lercanidipinhydrochlorid Sandoz 10 mg and 20 mg film-coated tablets. (Lercanidipine hydrochloride)

Public Assessment Report. Scientific discussion. Lercanidipinhydrochlorid Sandoz 10 mg and 20 mg film-coated tablets. (Lercanidipine hydrochloride) Public Assessment Report Scientific discussion Lercanidipinydroclorid Sandoz 10 mg and 20 mg film-coated tablets (Lercanidipine ydrocloride) DK/H/2360/001-002/DC 1 December 2015 Tis module reflects te

More information

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC. Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate)

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate) Public Assessment Report Scientific discussion Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution Paroxetine (as paroxetine mesilate) DK/H/0240/002/MR This module reflects the scientific discussion

More information

Public Assessment Report. Scientific discussion. Atorvastatin DK/H/1744/001-004/DC

Public Assessment Report. Scientific discussion. Atorvastatin DK/H/1744/001-004/DC Public Assessment Report Scientific discussion Atorvastatin Orifarm 10 mg 20 mg, 40 mg and 80 mg film-coated tablets Atorvastatin DK/H/1744/001-004/DC This module reflects the scientific discussion for

More information

Public Assessment Report Scientific discussion. Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC

Public Assessment Report Scientific discussion. Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC Public Assessment Report Scientific discussion Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Ranbaxy. The procedure

More information

Public Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC

Public Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC Public Assessment Report Scientific discussion Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Krka. The procedure

More information

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807 Public Assessment Report Scientific discussion Desloracell 5 mg, film-coated tablet (desloratadine) NL License RVG: 112807 Date: 6 July 2015 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC

Public Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC

More information

Public Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC

Public Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC Public Assessment Report Scientific discussion Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC This module reflects the scientific discussion for the approval of Tenofovir disoproxil Teva.

More information

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This

More information

HYDROCORTISONE 10 MG TABLETS

HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000

More information

Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296

Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296 Public Assessment Report UK National Procedure Perindopril 2 mg Tablets Perindopril 4 mg Tablets Perindopril 8 mg Tablets PL 20075/0294-0296 Accord Healthcare Limited 1 LAY SUMMARY This is a summary of

More information

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary of

More information

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the

More information

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval

More information

Public Assessment Report UKPAR

Public Assessment Report UKPAR Public Assessment Report UKPAR Amitriptyline 10 mg film-coated tablets Amitriptyline 25 mg film-coated tablets Amitriptyline 50 mg film-coated tablets (Amitriptyline hydrochloride) UK Licence No: PL 17907/0131-133

More information

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of

More information

Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets

Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets Public Assessment Report Decentralised Procedure Cefuroxime 250mg film-coated tablets Cefuroxime 500mg film-coated tablets Procedure No: UK Licence No: PL 35646/0020-0021 Alkem Pharma GmbH 1 LAY SUMMARY

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure MANEO 100 MG, 150 MG AND 200 MG PROLONGED-RELEASE TABLETS TRAMADOL HYDROCHLORIDE UK/H/4160/001-003/DC UK Licence No: PL 17871/0104-6 JENSON PHARMACEUTICAL

More information

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. Perindopril arginine Amlodipine FR/H/325-326-327/01-04/DC. Applicant: Servier

PUBLIC ASSESSMENT REPORT Scientific Discussion. Perindopril arginine Amlodipine FR/H/325-326-327/01-04/DC. Applicant: Servier Direction de l Evaluation des Médicaments et des Produits Biologiques PUBLIC ASSESSMENT REPORT Scientific Discussion COVERAM PERINDOPRIL ARGININE - AMLODIPINE SERVIER PERINDOPRIL ARGININE AMLODIPINE BIOPHARMA

More information

Summary Public Assessment Report. Generics

Summary Public Assessment Report. Generics Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin

More information

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498 Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was

More information

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy, Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public

More information

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levetiracetam 250 mg film-coated tablets PL 36390/0168; UK/H/5630/001/DC Levetiracetam 500 mg film-coated tablets PL 36390/0169; UK/H/5630/002/DC Levetiracetam

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Accord 100 mg/25 mg/200 mg Film-coated tablets Levodopa/Carbidopa/Entacapone Accord 150 mg/37.5 mg/200 mg Film-coated tablets

More information

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Dropodex 0.1% w/v eye drops, solution (Dexamethasone sodium phosphate) MT/H/0157/001/DC Date: 3 rd May, 2013 This module reflects the scientific discussion

More information

TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR

TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4

More information

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion Public Assessment Report Scientific discussion Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion (imipenem monohydrate/cilastatin sodium) NL/H/3075/001-002/DC

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Torrent 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Torrent, 75 mg/18.75 mg/200 mg film-coated

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Doc. Ref: CMDh/208/2005 Rev.5 December 2013 Decentralised Procedure Public Assessment Report Paracetamol Bristol-Myers Squibb 250 / 500 mg mit Erdbeer-/Vanillegeschmack Granulat in Beuteln ; 500 / 1000

More information

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets Public Assessment Report Scientific discussion Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets (Atorvastatin calcium trihydrate) NL/H/2994/001-004/DC Date: 16 March 2015 This module

More information

MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS

MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Steps taken after authorisation summary

More information

Public Assessment Report. Scientific discussion. Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft. (ibuprofen) NL/H/2810/001-002/MR

Public Assessment Report. Scientific discussion. Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft. (ibuprofen) NL/H/2810/001-002/MR Public Assessment Report Scientific discussion Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft (ibuprofen) 001-002/MR Date: 28 January 2016 This module reflects the scientific discussion for the approval

More information

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Meropenem 500 mg and 1 g, Powder for Solution for Injection or Infusion (Meropenem Trihydrate)

More information

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 12 Summary of Product Characteristics Page

More information

Public Assessment Report. Scientific discussion. Apotel 10 mg/ml, solution for infusion. (paracetamol) NL/H/2857/001/DC

Public Assessment Report. Scientific discussion. Apotel 10 mg/ml, solution for infusion. (paracetamol) NL/H/2857/001/DC Public Assessment Report Scientific discussion Apotel 10 mg/ml, solution for infusion (paracetamol) NL/H/2857/001/DC Date: 16 December 2014 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Ciclosporin Pharmachemie Capsules 25/50/100mg. (Ciclosporin)

Public Assessment Report. Scientific discussion. Ciclosporin Pharmachemie Capsules 25/50/100mg. (Ciclosporin) Public Assessment Report Scientific discussion Ciclosporin Pharmachemie Capsules 25/50/100mg (Ciclosporin) PA holder Alpharma ApS This module reflects the scientific discussion for the approval of Ciclosporin

More information

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 Public Assessment Report Scientific discussion Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 This module reflects the scientific discussion for the approval of Hydrokortison CCS. The procedure was

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure LANSOPRAZOLE 15 MG AND 30 MG ORODISPERSIBLE TABLETS (lansoprazole) Procedure No: UK Licence No: PL 35507/0118-0119 Lupin (Europe) Limited LAY SUMMARY Lansoprazole

More information

Public Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060

Public Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060 Public Assessment Report Decentralised Procedure PARACETAMOL 1000 MG TABLETS Procedure No: UK Licence No: PL 18866/0060 Rockspring Healthcare Ltd LAY SUMMARY On 17 January 2013 the Medicines and Healthcare

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Atorvastatin 10 mg film-coated Tablets Atorvastatin 20 mg film-coated Tablets Atorvastatin 40 mg film-coated Tablets Atorvastatin 80 mg film-coated Tablets

More information

Public Assessment Report. Decentralised Procedure. PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs

Public Assessment Report. Decentralised Procedure. PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs PAR Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated tabs Public Assessment Report Decentralised Procedure Bisoprolol 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg film-coated

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Compilation of individual product-specific guidance on demonstration of bioequivalence

Compilation of individual product-specific guidance on demonstration of bioequivalence 17 December 2014 EMA/CHMP/736403/2014 Committee for Medicinal Products for Human Use (CHMP) Compilation of individual product-specific guidance on demonstration of bioequivalence Initial batch of individual

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure IMATINIB TEVA UK 100 MG FILM-COATED TABLETS IMATINIB TEVA UK 400 MG FILM-COATED TABLETS (imatinib mesilate) Procedure No: UK Licence No: PL 00289/1516-1517

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Paracetamol 500 mg effervescent tablets Procedure No: UK/H/5662/001-002/DC UK Licence No: PL 36390/0177-0178 Cipla (EU) Limited Lay Summary Paracetamol

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:

More information

Public Assessment Report. Decentralised Procedure. Omega 3-acid-ethyl esters 1000mg Soft Capsules. Omega-3-acid ethyl esters 90

Public Assessment Report. Decentralised Procedure. Omega 3-acid-ethyl esters 1000mg Soft Capsules. Omega-3-acid ethyl esters 90 Public Assessment Report Decentralised Procedure Omega 3-acid-ethyl esters 1000mg Soft Capsules Omega-3-acid ethyl esters 90 Procedure No: UK Licence No: PL 00289/1756 and PL 00289/1778-80 Teva UK Limited

More information

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC Applicant: TEVA Pharma

More information

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC Public Assessment Report Scientific discussion Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets (pantoprazole) NL/H/2751/001-002/DC Date: 27 August 2014 This module reflects the scientific

More information

Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution

Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution Public Assessment Report Decentralised Procedure Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate) Procedure No: UK Licence No: PL

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC Direction NEURHO /DP3 Neurologie-Psychiatrie-Antalgie-Rhumatologie- Pneumologie-ORL-Ophtalmologie-Stups et psychotropes PUBLIC ASSESSMENT REPORT Scientific Discussion ASPROFLASH 500mg, Coated Tablets Acetylsalicylic

More information

Public Assessment Report. Scientific discussion. Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches.

Public Assessment Report. Scientific discussion. Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches. Public Assessment Report Scientific discussion Rivamylan 4.6 mg /24 hours and 9.5 mg /24 hours, transdermal patches (rivastigmine) NL/H/2958/001-002/DC Date: 30 March 2015 This module reflects the scientific

More information

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics

More information

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC Public Assessment Report Scientific discussion Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC This module reflects the scientific discussion for the approval of Prednisolon mibe. The procedure

More information

Summary Public Assessment Report. non-generics. (Acetylcysteine) PT/H/873/001/MR

Summary Public Assessment Report. non-generics. (Acetylcysteine) PT/H/873/001/MR Summary Public Assessment Report non-generics Acetilcisteína Friulchem (Acetylcysteine) Summary PAR non-generics 1/8 Acetilcisteína Friulchem Acetilcisteína Friulchem Acetylcysteine 1200 mg effervescent

More information

Public Assessment Report. Decentralised Procedure. Omeprazole 10mg Gastro-resistant Capsules, hard. Omeprazole 20mg Gastro-resistant Capsules, hard

Public Assessment Report. Decentralised Procedure. Omeprazole 10mg Gastro-resistant Capsules, hard. Omeprazole 20mg Gastro-resistant Capsules, hard Public Assessment Report Decentralised Procedure Omeprazole 10mg Gastro-resistant Capsules, hard Omeprazole 20mg Gastro-resistant Capsules, hard Omeprazole 40mg Gastro-resistant Capsules, hard (UK/H/4423/001-003/DC)

More information

Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)

Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate) Public Assessment Report Decentralised Procedure Cefadroxil 250 mg/5 ml granules for oral suspension (Cefadroxil monohydrate) UK licence no: PL 34088/0033 Alkaloid-INT d.o.o. 1 Cefadroxil 250 mg/5 ml granules

More information

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics

More information

Public Assessment Report. Decentralised Procedure. PAR Flucloxacillin 250 mg & 500 mg Capsules. Flucloxacillin 500 mg Capsules.

Public Assessment Report. Decentralised Procedure. PAR Flucloxacillin 250 mg & 500 mg Capsules. Flucloxacillin 500 mg Capsules. Public Assessment Report Decentralised Procedure Flucloxacillin 250 mg Capsules Flucloxacillin 500 mg Capsules (flucloxacillin) Procedure No: UK/H/1101/001-002/DC UK Licence No: PL 21880/0017-0018 Medreich

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Addaven (chromic chloride hexahydrate, copper chloride dihydrate, ferric chloride hexahydrate, manganese chloride tetrahydrate, potassium iodide, sodium fluoride,

More information

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol)

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol) Public Assessment Report Decentralised Procedure Pemetrexed 25 mg/ml Concentrate for Solution for Infusion (pemetrexed ditrometamol) Procedure No: UK Licence No: PL 24668/0187 Caduceus Pharma Ltd 1 LAY

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT VIRBAKOR 20 mg film-coated tablet for dogs Date: 03/11/2014 French agency for food, environnemental

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion 1) Risedronat Actavis 5 mg Filmtabletten, 30 mg Filmtabletten, 35 mg einmal wöchentlich Filmtabletten 2) Bifodron 5 mg Filmtabletten, 30 mg Filmtabletten,

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Ibuprofen and phenylephrine hydrochloride 200mg/5mg film-coated tablets Procedure No: UK Licence No: PL 17780/0563 Winthrop Pharmaceuticals UK Limited LAY

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125

More information

LOSARTAN POTASSIUM 12.5, 25MG, 50MG & 100MG FILM- COATED TABLETS PL 14017/ UKPAR TABLE OF CONTENTS

LOSARTAN POTASSIUM 12.5, 25MG, 50MG & 100MG FILM- COATED TABLETS PL 14017/ UKPAR TABLE OF CONTENTS LOSARTAN POTASSIUM 12.5, 25MG, 50MG & 100MG FILM- COATED TABLETS PL 14017/0140-3 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 16 Summary of Product

More information

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd. Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY

More information

Instantaneous Rate of Change:

Instantaneous Rate of Change: Instantaneous Rate of Cange: Last section we discovered tat te average rate of cange in F(x) can also be interpreted as te slope of a scant line. Te average rate of cange involves te cange in F(x) over

More information

7.6 Complex Fractions

7.6 Complex Fractions Section 7.6 Comple Fractions 695 7.6 Comple Fractions In tis section we learn ow to simplify wat are called comple fractions, an eample of wic follows. 2 + 3 Note tat bot te numerator and denominator are

More information

Public Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC

Public Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC Public Assessment Report Decentralised Procedure Tenofovir Zentiva 245 mg Film-coated Tablets Tenofovir disoproxil fumarate UK licence no: PL 17780/0573 Winthrop Pharmaceuticals UK Limited 1 LAY SUMMARY

More information

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o. Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This

More information

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES

STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE

More information

Decentralised Procedure. RMS Day 70 Preliminary Assessment Report. Paracetamol Pharmacin 1000mg, tablets (paracetamol) NL/H/2791/001/DC

Decentralised Procedure. RMS Day 70 Preliminary Assessment Report. Paracetamol Pharmacin 1000mg, tablets (paracetamol) NL/H/2791/001/DC December 2011 CMDh/202/2005 Decentralised Procedure RMS Day 70 Preliminary Assessment Report NON-CLINICAL AND CLINICAL ASSESSMENT OF A GENERIC APPLICATION Paracetamol Pharmacin 1000mg, tablets (paracetamol)

More information

Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS

Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure TEMOZOLOMIDE RELIANCE 20 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 100 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 140 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 180

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Thorens 10 000 I.U. /ml oral drops, solution Thorens 25 000 I.U. /2.5 ml oral solution Deltius 10 000 I.U. /ml oral drops, solution Deltius 25 000 I.U.

More information

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS

ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics

More information

Dexamethasone 500 microgram Tablets PL 42701/0001 UK PAR

Dexamethasone 500 microgram Tablets PL 42701/0001 UK PAR Dexamethasone 500 microgram Tablets PL 42701/0001 UK PAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 14 Steps taken after the initial procedure - summary

More information

Guide for the Bioequivalence -Module 5

Guide for the Bioequivalence -Module 5 Guide for the Bioequivalence -Module 5 Prepared by the Technical Subcommittee s experts under the supervision of Dr. Rita Karam, Head of Quality Assurance of Pharmaceutical Products 1 INTRODUCTION Two

More information

Montelukast 10mg film-coated tablets PL 17907/0474

Montelukast 10mg film-coated tablets PL 17907/0474 Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page

More information

CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS

CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 8 Steps taken after authorisation

More information

OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole)

OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole) OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES (omeprazole) PL 36884/0001, PL 36884/0002, PL 36884/0003, PL 36884/0004, PL 36884/0005 AND PL 36884/0006 UKPAR TABLE OF CONTENTS Lay Summary

More information

InVita D3 25,000 IU oral solution PL 24837/0039

InVita D3 25,000 IU oral solution PL 24837/0039 InVita D3 25,000 IU oral solution PL 24837/0039 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 12 Summary of Product Characteristics Page 13 Patient

More information

Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR

Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for

More information

Public Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01

Public Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01 Public Assessment Report Scientific discussion Tostrex (Testosterone) SE/H/571/01 This module reflects the scientific discussion for the approval of Tostrex. The procedure was finalised at 2006-04-07.

More information

Sterilised Water for Injections PL 08801/0057 UKPAR

Sterilised Water for Injections PL 08801/0057 UKPAR Sterilised Water for Injections PL 08801/0057 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Urostemol Men capsules THR 02855/0240

Urostemol Men capsules THR 02855/0240 Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of

More information

Regulation of Bioavailability and Bioequivalence Studies

Regulation of Bioavailability and Bioequivalence Studies Regulation of Bioavailability and Bioequivalence Studies (Amended Date: 2015-03-06) 1.Promulgated on April 02, 2009 2.Amended on January 31, 2013 3.Amended on March 6, 2014. Revised articles include Article

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January

More information

Math 113 HW #5 Solutions

Math 113 HW #5 Solutions Mat 3 HW #5 Solutions. Exercise.5.6. Suppose f is continuous on [, 5] and te only solutions of te equation f(x) = 6 are x = and x =. If f() = 8, explain wy f(3) > 6. Answer: Suppose we ad tat f(3) 6. Ten

More information

PUBLIC ASSESSMENT REPORT. Decentralised Procedure DE/H/2924/001/DC. Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets

PUBLIC ASSESSMENT REPORT. Decentralised Procedure DE/H/2924/001/DC. Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets Federal Institute for Drugs and Medical Devices PUBLIC ASSESSMENT REPORT Decentralised Procedure DE/H/2924/001/DC Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets Calcium carbonate, Cholecalciferol

More information